|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2000-10-23
|
|
pubmed:abstractText |
The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0939-5555
|
|
pubmed:author |
pubmed-author:AtzpodienJJ,
pubmed-author:AulitzkyEE,
pubmed-author:BruggerWW,
pubmed-author:EngertAA,
pubmed-author:Feuring-BuskeMM,
pubmed-author:GramatzkiMM,
pubmed-author:HallekMM,
pubmed-author:HiddemannWW,
pubmed-author:HillerEE,
pubmed-author:KnebaMM,
pubmed-author:OstermannHH,
pubmed-author:TrümperLL,
pubmed-author:UnterhaltMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
493-500
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11043420-Adult,
pubmed-meshheading:11043420-Aged,
pubmed-meshheading:11043420-Antibodies, Monoclonal,
pubmed-meshheading:11043420-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:11043420-Antineoplastic Agents,
pubmed-meshheading:11043420-Female,
pubmed-meshheading:11043420-Humans,
pubmed-meshheading:11043420-Lymphoma, Follicular,
pubmed-meshheading:11043420-Male,
pubmed-meshheading:11043420-Middle Aged,
pubmed-meshheading:11043420-Neoplasm Staging,
pubmed-meshheading:11043420-Recurrence,
pubmed-meshheading:11043420-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
|
|
pubmed:affiliation |
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University of München, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
